GABA Deficiency and Hormonal Imbalances: The Role of Progesterone in GABAergic Signaling

Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the human brain [1]. By putting the brakes on neuronal excitability, GABA helps maintain the delicate balance between excitation and inhibition that allows the nervous system to function properly. Given this role, GABAergic signaling is involved in a variety of processes, including sleep, stress regulation, emotional processing, cognition, and the control of neuronal excitability [1–3].

Consequently, impaired GABAergic signaling has been implicated in several neurological and psychiatric conditions, including anxiety disorders, depression, epilepsy, and sleep disturbances [4–6]. However, the popular term “GABA deficiency” can be somewhat misleading. Unlike a vitamin or mineral deficiency, there is no single clinical measurement that establishes whether someone is simply deficient in GABA. Reduced inhibitory signaling can instead result from alterations in GABA synthesis, release, metabolism, receptor expression, receptor sensitivity, or the substances that modulate GABA receptors. For a broader discussion of this distinction, see What Are the Symptoms of GABA Deficiency?

Among the most important endogenous modulators of the GABA system are steroid hormones and their metabolites. Progesterone is particularly significant because it can be converted into the neuroactive steroid allopregnanolone, which strongly influences GABA receptor activity [7,8]. This connection may help explain why changes in reproductive hormones can influence mood, anxiety, stress sensitivity, and sleep. We will explore these relationships in today’s article.

Understanding the GABA System

GABA is primarily synthesized from the excitatory neurotransmitter glutamate through the activity of glutamic acid decarboxylase (GAD). Once released from inhibitory neurons, GABA binds to receptors on neighboring cells and reduces their likelihood of firing.

The GABA-A receptor is especially important. It is an ion channel that allows chloride ions to move across neuronal membranes when activated. In the mature central nervous system, this generally makes neurons less excitable and contributes to the braking function of the GABA system.

GABA-A receptor activity is also influenced by several endogenous molecules. Of particular relevance to hormonal health are neuroactive steroids: steroid molecules produced in peripheral organs or within the nervous system that can rapidly modify neuronal activity [9,10].

Allopregnanolone is one of the best-studied examples. Derived from progesterone, allopregnanolone is a potent positive allosteric modulator of GABA-A receptors [11]. Rather than replacing GABA, it enhances the receptor’s response to GABA, strengthening inhibitory signaling. This creates an important biological link between progesterone and GABA-A receptor activity. The conversion involves enzymes including 5α-reductase and 3α-hydroxysteroid dehydrogenase, and changes anywhere along this pathway may influence neurosteroid availability and GABAergic function.

Progesterone, Allopregnanolone, and GABA

Progesterone is perhaps best known as a reproductive hormone. Its levels increase substantially during the luteal phase of the menstrual cycle following ovulation, while dramatically higher concentrations occur during pregnancy. Progesterone then falls toward the end of the menstrual cycle if pregnancy does not occur and declines markedly following childbirth. Some neurological effects associated with progesterone are thought to result from its conversion into allopregnanolone rather than from progesterone acting directly on classical progesterone receptors.

Allopregnanolone binds to specific sites on GABA-A receptors and enhances their activity. At physiologically relevant concentrations, it can increase the effects of GABA and strengthen neuronal inhibition. Neurosteroid-sensitive GABA receptors are consequently involved in processes including emotional regulation, stress responses, sleep, and neuronal excitability.

As neurosteroid concentrations fluctuate, the brain continuously adapts. Changes in allopregnanolone exposure can alter the expression and subunit composition of GABA-A receptors. Both hormone concentrations and the nervous system’s sensitivity to changes in those concentrations may therefore be important [12,13].

The Menstrual Cycle and GABAergic Signaling

The menstrual cycle provides perhaps the clearest example of the dynamic interaction between reproductive hormones and the GABA system.

Following ovulation, progesterone concentrations increase during the luteal phase. Allopregnanolone concentrations generally increase alongside progesterone because progesterone provides the precursor from which it is synthesized. As menstruation approaches, progesterone and allopregnanolone subsequently decline. This changing neurosteroid environment requires the GABAergic system to adapt.

For most individuals, these fluctuations occur without severe psychological consequences. However, some people appear particularly sensitive to changes in neuroactive steroid signaling. Premenstrual dysphoric disorder (PMDD) provides an important example. PMDD is characterized by recurring mood symptoms such as marked irritability, affective instability, anxiety, or depressed mood that emerge during the late luteal phase and improve shortly after menstruation begins.

Importantly, PMDD does not appear to result simply from abnormally high or low progesterone concentrations. Research increasingly suggests that altered sensitivity to normal fluctuations in ovarian hormones, allopregnanolone, and GABA-A receptor signaling may be more important [18,19].

In other words, the problem may sometimes involve the brain’s response to changing hormones rather than the absolute concentration of the hormones themselves. This may also help explain why changes in GABA-related signaling do not always produce the same emotional response in every person. Our article Why GABA Makes Some People More Anxious, Not Less explores the broader biology behind paradoxical responses.

Stress, GABA, and Hormones

GABAergic signaling contributes to regulation of the hypothalamic-pituitary-adrenal (HPA) axis, one of the body’s principal stress-response systems. Neuroactive steroids such as allopregnanolone can help regulate neuronal circuits involved in the response to stressful experiences [14,15]. Acute stress can alter neurosteroid synthesis, potentially contributing to adaptive changes in GABAergic inhibition. Chronic or severe stress, however, may disrupt these mechanisms.

Altered allopregnanolone concentrations or impaired neurosteroid signaling have been reported in several stress-related psychiatric conditions. Experimental evidence also indicates that prolonged stress can influence both neurosteroid biosynthesis and GABA-A receptor composition. This creates a potentially bidirectional relationship in which hormonal changes can modify the GABA system while stress itself can influence neurosteroid production and GABAergic function.

Rather than operating independently, the endocrine and nervous systems form an interconnected regulatory network. For more on this relationship, read The Connection Between GABA Deficiency and Chronic Stress.

What About Estrogen?

Progesterone is not the only reproductive hormone capable of influencing GABAergic neurotransmission. Estrogens interact with multiple neurotransmitter systems, including GABA, serotonin, dopamine, and glutamate. Estrogen can influence GABA synthesis, receptor expression, and neuronal circuitry, although its effects vary considerably among brain regions and physiological circumstances [16,17]. This becomes particularly important during periods when estrogen and progesterone change simultaneously, including menstruation, pregnancy, postpartum, and perimenopause.

Consequently, symptoms occurring during hormonal transitions cannot necessarily be attributed to low progesterone or low GABA alone. They may reflect interactions among multiple hormones, neurotransmitters, receptors, stress systems, and individual biological susceptibility.

Perimenopause and Menopause

The menopausal transition represents another period of substantial endocrine change. During perimenopause, ovarian hormone production becomes increasingly variable as reproductive function declines. Progesterone exposure may become less consistent as ovulation becomes irregular, while estrogen concentrations can fluctuate substantially before eventually declining.

These changes coincide with increased rates of symptoms such as sleep disturbance and mood changes in some individuals. Altered neurosteroid-GABA interactions have therefore attracted interest as one possible contributor to neurological symptoms during reproductive aging [10,20].

Progesterone-derived neurosteroid signaling may change as ovarian function declines, while the GABAergic system itself also undergoes age-related alterations. Nevertheless, menopause-related symptoms are multifactorial. Hormonal changes interact with aging, sleep, psychological stress, physical health, and numerous other biological and environmental influences. Current evidence does not support attributing these symptoms to a single GABA or progesterone deficiency.

Beyond the Idea of “GABA Deficiency”

Understanding the progesterone-GABA relationship illustrates why describing symptoms simply as a GABA deficiency can be problematic. Someone could theoretically have adequate GABA concentrations but altered GABA receptor expression or sensitivity. Another person might experience altered production of neuroactive steroids. In other circumstances, the ability of GABAergic neurons to release or recycle GABA could be affected.

Likewise, measuring progesterone alone does not necessarily reveal what is happening within the brain. Progesterone must undergo enzymatic conversion to produce allopregnanolone, while the effects of allopregnanolone ultimately depend on the composition and responsiveness of GABA-A receptors.

The emerging picture is therefore one of GABAergic tone rather than a simple deficiency.

Conclusion

The connection between progesterone and GABA demonstrates how closely intertwined the endocrine and nervous systems are.

It is worth emphasizing that progesterone is much more than a reproductive hormone. Through its conversion to allopregnanolone, it can influence one of the brain’s most important inhibitory signaling systems. Allopregnanolone enhances GABA-A receptor activity and contributes to the regulation of neuronal excitability, stress responses, mood, and sleep. Yet the relationship is dynamic: normal fluctuations in progesterone and allopregnanolone require corresponding adaptations in GABA receptors. For some individuals, altered sensitivity to these changes may contribute to symptoms associated with PMDD, reproductive transitions, or certain neuropsychiatric conditions.

This also explains why the concept of GABA deficiency should be approached cautiously. Effective GABAergic signaling depends not merely on how much GABA is present, but on neurotransmitter synthesis and release, receptor number and composition, neurosteroid concentrations, hormonal fluctuations, and the brain’s capacity to adapt to those fluctuations. Rather than viewing hormones and neurotransmitters as separate systems, modern neuroendocrinology increasingly reveals them as components of the same highly interconnected network. Progesterone and allopregnanolone provide one of the clearest examples: reproductive hormones have the capacity to shape the inhibitory architecture of the brain.

 

References

1. Marilovtseva EV, Abdurazakov A, Kurishev AO, Mikhailova VA, Golimbet VE. The role of GABA pathway components in pathogenesis of neurodevelopmental disorders. Int J Mol Sci. 2025;26(19):9492. doi:10.3390/ijms26199492
2. Arora I, Mal P, Arora P, Paul A, Kumar M. GABAergic implications in anxiety and related disorders. Biochem Biophys Res Commun. 2024;724:150218. doi:10.1016/j.bbrc.2024.150218
3. Bowery NG, Smart TG. GABA and glycine as neurotransmitters: A brief history. Br J Pharmacol. 2006;147(suppl 1):S109-S119. doi:10.1038/sj.bjp.0706443
4. Oishi Y, Saito YC, Sakurai T. GABAergic modulation of sleep-wake states. Pharmacol Ther. 2023;249:108505. doi:10.1016/j.pharmthera.2023.108505
5. Kalueff AV, Nutt DJ. Role of GABA in anxiety and depression. Depress Anxiety. 2007;24(7):495-517. doi:10.1002/da.20262
6. Plante DT, Jensen JE, Winkelman JW. The role of GABA in primary insomnia. Sleep. 2012;35(6):741-742. doi:10.5665/sleep.1854
7. Smith SS, Waterhouse BD, Chapin JK, Woodward DJ. Progesterone alters GABA and glutamate responsiveness: A possible mechanism for its anxiolytic action. Brain Res. 1987;400(2):353-359. doi:10.1016/0006-8993(87)90634-2
8. Stefaniak M, Dmoch-Gajzlerska E, Jankowska K, Rogowski A, Kajdy A, Maksym RB. Progesterone and its metabolites play a beneficial role in affect regulation in the female brain. Pharmaceuticals (Basel). 2023;16(4):520. doi:10.3390/ph16040520
9. Akk G, Covey DF, Evers AS, Steinbach JH, Zorumski CF, Mennerick S. Mechanisms of neurosteroid interactions with GABA-A receptors. Pharmacol Ther. 2007;116(1):35-57. doi:10.1016/j.pharmthera.2007.03.004
10. Gilfarb RA, Leuner B. GABA system modifications during periods of hormonal flux across the female lifespan. Front Behav Neurosci. 2022;16:802530. doi:10.3389/fnbeh.2022.802530
11. Maguire J. Neuroactive steroids and GABAergic involvement in the neuroendocrine dysfunction associated with major depressive disorder and postpartum depression. Front Cell Neurosci. 2019;13:83. doi:10.3389/fncel.2019.00083
12. Stell BM, Brickley SG, Tang CY, Farrant M, Mody I. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABA-A receptors. Proc Natl Acad Sci U S A. 2003;100(24):14439-14444. doi:10.1073/pnas.2435457100
13. Wang M. Neurosteroids and GABA-A receptor function. Front Endocrinol (Lausanne). 2011;2:44. doi:10.3389/fendo.2011.00044
14. Almeida FB, Pinna G, Barros HMT. The role of HPA axis and allopregnanolone on the neurobiology of major depressive disorders and PTSD. Int J Mol Sci. 2021;22(11):5495. doi:10.3390/ijms22115495
15. Turkmen S, Backstrom T, Wahlstrom G, Andreen L, Johansson I. Tolerance to allopregnanolone with focus on the GABA-A receptor. Br J Pharmacol. 2011;162(2):311-327. doi:10.1111/j.1476-5381.2010.01059.x
16. Wojtowicz T, Mozrzymas JW. Estradiol and GABAergic transmission in the hippocampus. Vitam Horm. 2010;82:279-300. doi:10.1016/S0083-6729(10)82015-1
17. Maggi A, Perez J. Estrogen-induced up-regulation of gamma-aminobutyric acid receptors in the CNS of rodents. J Neurochem. 1986;47(6):1793-1797. doi:10.1111/j.1471-4159.1986.tb13090.x
18. Backstrom T, Das R, Bixo M. Positive GABA-A receptor-modulating steroids and their antagonists: Implications for clinical treatments. J Neuroendocrinol. 2022;34(2):e13013. doi:10.1111/jne.13013
19. Hantsoo L, Payne JL. Towards understanding the biology of premenstrual dysphoric disorder: From genes to GABA. Neurosci Biobehav Rev. 2023;149:105168. doi:10.1016/j.neubiorev.2023.105168
20. Haufe A, Baker FC, Leeners B. The role of ovarian hormones in the pathophysiology of perimenopausal sleep disturbances: A systematic review. Sleep Med Rev. 2022;66:101710. doi:10.1016/j.smrv.2022.101710